Postβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli
Antibiotics · 11.09.2025 · 14 (9) · 915
DOI: 10.3390/antibiotics14090915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 11.09.2025. Verfasst von Ru Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: MOA Laboratory of Risk Assessment for Quality and Safety of Livestock and Poultry Products, Wuhan 430070, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program (2023YFD1800901) and the National Natural Science Foundation of China (32273063), National Key Research and Development Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background/Objectives: Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli poses a significant global health challenge, as it leads to antimicrobial treatment failure and is associated with elevated mortality rates. The use of β-lactam/β-lactamase inhibitor combinations offers an alternative approach for combating ESBL-producing bacteria. Ceftriaxone (CRO) and sulbactam have been coadministered in the clinical settings; however, discrepancies in their pharmacokinetics raise concerns regarding the rationality of this combination.
Methods
This study was designed to investigate the postβ-lactamase inhibitor effect (PLIE) under both static and dynamic conditions, with the aim of supporting the clinical application of this combination.
Results
The minimum inhibitory concentration (MIC) of CRO/SBT (2:1 ratio) against E. coli NCTC 13353 was determined to be 32/16 μg/mL. The PLIEs were determined to be −1.26, −0.57, and 0.37 h at CRO/SBT concentrations ranging from 1/2 MIC to 2 MIC, respectively. The results of CRO concentration, β-lactamase activity, blaCTX-M-15 expression, and cell morphology collectively support that SBT exerts PLIEs and protects against the antibacterial activity of CRO. In the dynamic hollow-fiber infection model, CRO monotherapy showed no inhibitory effect on E. coli, whereas CRO/SBT combination therapy rapidly eliminated SBT, achieved comparable bactericidal effects, prolonged CRO exposure, and maintained low β-lactamase activity levels.
Conclusions
In conclusion, CRO/SBT exerts an inhibitory effect on enzyme-producing strains by being able to produce PLIE to maintain the inhibition of β-lactamase.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MOA Laboratory of Risk Assessment for Quality and Safety of Livestock and Poultry Products, Wuhan 430070, China.
- National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for the Detection of Veterinary Drug Residues, Wuhan 430070, China.
- Guangdong Hengqin Xinchuangyi Biomedical Co., Ltd., Zhuhai 519000, China.
- Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Huazhong Agricultural University, Wuhan 430070, China.
Förderung
- the National Key Research and Development Program (2023YFD1800901) and the National Natural Science Foundation of China (32273063)
- National Key Research and Development Program
- National Natural Science Foundation of China
Zitieren
APA
Wang, R., Mi, K., Lu, A., Zhang, C., Sun, L., Chen, Y., Pan, Y., Tao, Y., & Huang, L. (2025). Postβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli. Antibiotics, 14(9), 915. https://doi.org/10.3390/antibiotics14090915
Vancouver
Wang R, Mi K, Lu A, Zhang C, Sun L, Chen Y, et al. Postβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli. Antibiotics. 2025;14(9):915. doi:10.3390/antibiotics14090915
BibTeX
@article{Wang2025,
author = {Wang, Ru and Mi, Kun and Lu, Aihua and Zhang, Chengyang and Sun, Lei and Chen, Yuxiang and Pan, Yuanhu and Tao, Yanfei and Huang, Lingli},
title = {Postβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {9},
pages = {915},
doi = {10.3390/antibiotics14090915}
}
EUVIMED